CAJ | 학술논문

目的：观察缬沙坦对糖尿病肾病患者临床治疗效果和安全情况。方法将该研究组收治糖尿病肾病患者随机分为对照组、缬沙坦80 mg和160 mg治疗组，记录施治前后各项指标。结果缬沙坦160 mg治疗组的尿蛋白下降及收缩压下降情况较另外2组显著。结论缬沙坦能够改善糖尿病肾病患者的尿蛋白、血压和肾功能，且缬沙坦治疗剂量达到160 mg时更具优越作用。
목적：관찰힐사탄대당뇨병신병환자림상치료효과화안전정황。방법장해연구조수치당뇨병신병환자수궤분위대조조、힐사탄80 mg화160 mg치료조，기록시치전후각항지표。결과힐사탄160 mg치료조적뇨단백하강급수축압하강정황교령외2조현저。결론힐사탄능구개선당뇨병신병환자적뇨단백、혈압화신공능，차힐사탄치료제량체도160 mg시경구우월작용。
Objective To observe the valsartan on clinical outcomes in patients with diabetic nephropathy and security situation. Methods In this study, patients with kidney disease were randomly divided into a control group treated diabetic group, valsartan 80 mg and 160 mg treatment group recorded blood pressure, blood urea nitrogen, creatinine, 24 h urinary protein, serum albumin and other indicators before and after treatment. Results Treatment with valsartan 160 mg group systolic blood pressure decreased urinary protein loss and the situation than the other two groups significantly; all patients plasma valsartan albumin increased. Conclusion Valsartan can improve urinary protein in patients with diabetic nephropathy, blood pressure and renal function, and valsartan dose of more favorable effect when 160mg.